Double-blind randomized proof-of-concept trial of canakinumab in patients with COVID-19 associated cardiac injury and heightened inflammation.
COVID-19
Canakinumab
Interleukin-1
Myocardial injury
Journal
European heart journal open
ISSN: 2752-4191
Titre abrégé: Eur Heart J Open
Pays: England
ID NLM: 9918282081406676
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
11
04
2021
revised:
10
05
2021
entrez:
4
8
2022
pubmed:
5
8
2022
medline:
5
8
2022
Statut:
epublish
Résumé
In coronavirus disease 2019 (COVID-19), myocardial injury is associated with systemic inflammation and higher mortality. Our aim was to perform a proof of concept trial with canakinumab, a monoclonal antibody to interleukin-1β, in patients with COVID-19, myocardial injury, and heightened inflammation. This trial required hospitalization due to COVID-19, elevated troponin, and a C-reactive protein concentration more than 50 mg/L. The primary endpoint was time to clinical improvement at Day 14, defined as either an improvement of two points on a seven-category ordinal scale or discharge from the hospital. The secondary endpoint was mortality at Day 28. Forty-five patients were randomly assigned to canakinumab 600 mg ( There was no difference in time to clinical improvement at Day 14 in patients treated with canakinumab, and no safety concerns were identified. Future studies could focus on high dose canakinumab in the treatment arm and assess efficacy outcomes at Day 28.
Identifiants
pubmed: 35923169
doi: 10.1093/ehjopen/oeab002
pii: oeab002
pmc: PMC9242054
doi:
Types de publication
Journal Article
Comment
Langues
eng
Pagination
oeab002Commentaires et corrections
Type : CommentOn
Informations de copyright
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.
Références
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Clin Pharmacokinet. 2012 Jun 1;51(6):e1-18
pubmed: 22550964
JAMA Cardiol. 2020 Jul 1;5(7):811-818
pubmed: 32219356
Lancet. 2021 May 01;397(10285):1637-1645
pubmed: 33933206
Autoimmun Rev. 2020 Jul;19(7):102567
pubmed: 32376392
Eur Heart J. 2020 Sep 1;41(32):3038-3044
pubmed: 32882706
N Engl J Med. 2009 Jun 4;360(23):2416-25
pubmed: 19494217
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
J Am Coll Cardiol. 2020 Sep 8;76(10):1244-1258
pubmed: 32652195
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
BMC Med. 2010 Mar 22;8:17
pubmed: 20307281
N Engl J Med. 2021 Jan 7;384(1):20-30
pubmed: 33332779
J Am Coll Cardiol. 2020 Aug 4;76(5):533-546
pubmed: 32517963
N Engl J Med. 2021 Apr 22;384(16):1491-1502
pubmed: 33631065
Clin Cardiol. 2020 Oct;43(10):1055-1063
pubmed: 32830894
Lancet Rheumatol. 2020 Aug;2(8):e457-ee458
pubmed: 32835251
Circ Res. 2016 Jan 8;118(1):145-56
pubmed: 26837745
J Am Coll Cardiol. 2018 Oct 30;72(18):2231-2264
pubmed: 30153967
N Engl J Med. 2020 Dec 10;383(24):2333-2344
pubmed: 33085857
JAMA. 1994 Jun 15;271(23):1836-43
pubmed: 8196140
JAMA Cardiol. 2020 Jul 1;5(7):802-810
pubmed: 32211816
Blood. 2011 Apr 7;117(14):3720-32
pubmed: 21304099
Eur Heart J. 2020 Jun 7;41(22):2092-2112
pubmed: 32511724